SCHEMBL7908951

SCHEMBL7908951

CCOC(=O)c1ncccc1CN

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.57
TDP2 O95551 3/20 0.45
KDM4E B2RXH2 3/20 0.45
HSD17B10 Q99714 2/20 0.45
PDE4A P27815 1/20 0.45
CASP1 P29466 1/20 0.45
CYP1A2 P05177 2/20 0.44
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
DPP4 P27487 1/20 0.42
ELANE P08246 1/20 0.42
MAPT P10636 1/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TP53 P04637 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30484547 1.00 BRD4 (0.57) BRD4TDP2KDM4EHSD17B10PDE4A
SCHEMBL28472394 0.89 BRD4 (0.61) BRD4TDP2KDM4EHSD17B10PDE4A
SCHEMBL16790450 0.88 ALDH1A1 (0.46) BRD4KDM4ECYP1A2TSHRELANE
SCHEMBL14895437 0.88 BRD4 (0.58) BRD4TDP2KDM4EHSD17B10PDE4A
SCHEMBL18132204 0.86 BRD4 (0.58) BRD4TDP2KDM4EHSD17B10PDE4A
SCHEMBL3369457 0.84 BRD4 (0.57) BRD4TDP2KDM4EHSD17B10PDE4A
SCHEMBL127810 0.84 BRD4 (0.57) BRD4TDP2KDM4EHSD17B10PDE4A
SCHEMBL28759101 0.84 L3MBTL1 (0.55) BRD4KDM4EHSD17B10CYP1A2HTT
SCHEMBL29922777 0.81 BRD4 (0.60) BRD4TDP2KDM4EHSD17B10PDE4A
SCHEMBL1187172 0.81 BRD4 (0.60) BRD4TDP2KDM4EHSD17B10PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10669242-B2 Clostridium difficile toxin inhibitors Venenum Biodesign, LLC (US) 2020-06-02 US disclosed
US-20190194147-A1 Novel Clostridium Difficile Toxin Inhibitors Venenum Biodesign, LLC (US) 2019-06-27 US disclosed
WO-2017214359-A1 NOVEL CLOSTRIDIUM DIFFICILE TOXIN INHIBITORS VENENUM BIODESIGN LLC (US) 2017-12-14 WO disclosed
WO-2015161830-A1 HETEROAROMATIC DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-10-29 WO disclosed
WO-2010052222-A1 (DIHYDRO)NAPHTHYRIDINONE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS EVOTEC NEUROSCIENCES GMBH (DE) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190194147-A1 Novel Clostridium Difficile Toxin Inhibitors GABRA5, GABRA1, GABRA4 BRD4 1340/4885TDP2 4110/4885KDM4E 1334/4885
US-10669242-B2 Clostridium difficile toxin inhibitors GABRA5, GABRA1, GABBR2 BRD4 1751/4885TDP2 3830/4885KDM4E 1625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.